TABLE 2.
Geometric means and univariate and adjusted geometric mean ratios with 95% CI comparing the Cmaxs and the AUC0–6 of anti-TB drugs in patients with DM versus patients without DMa
| Drug, phase, and parameter | Geometric mean value for patients with: |
GMR (95% CI) | P value for GMR | Adjusted GMR (95% CI) | P value for adjusted GMR | |
|---|---|---|---|---|---|---|
| No diabetes | Diabetes | |||||
| Rifampin | ||||||
| Intensive phase | ||||||
| Cmax (μg/ml) | 4.32 | 3.63 | 0.84 (0.62, 1.14) | 0.26 | 0.75 (0.48, 1.19) | 0.22 |
| AUC0–6 (μg · h/ml) | 15.34 | 12.19 | 0.79 (0.60, 1.05) | 0.11 | 0.79 (0.55, 1.15) | 0.22 |
| Continuation phase | ||||||
| Cmax (μg/ml) | 2.98 | 3.81 | 1.28 (0.90, 1.82) | 0.17 | 1.00 (0.67, 1.49) | 0.99 |
| AUC0–6 (μg · h/ml) | 11.13 | 14.46 | 1.30 (0.92, 1.84) | 0.14 | 1.08 (0.73, 1.61) | 0.69 |
| Isoniazid | ||||||
| Intensive phase | ||||||
| Cmax (μg/ml) | 7.91 | 5.97 | 0.75 (0.58, 0.98) | 0.03 | 0.77 (0.56, 1.03) | 0.08 |
| AUC0–6 (μg · h/ml) | 26.84 | 20.0 | 0.75 (0.57, 0.97) | 0.03 | 0.74 (0.54, 1.01) | 0.06 |
| Continuation phase | ||||||
| Cmax (μg/ml) | 7.63 | 7.42 | 0.97 (0.72, 1.32) | 0.86 | 0.82 (0.53, 1.27) | 0.38 |
| AUC0–6 (μg · h/ml) | 26.79 | 23.79 | 0.89 (0.65, 1.21) | 0.45 | 0.75 (0.50, 1.14) | 0.18 |
| Pyrazinamide, intensive phase | ||||||
| Cmax (μg/ml) | 32.75 | 21.59 | 0.66 (0.51, 0.85) | 0.002 | 0.74 (0.56, 0.97) | 0.03 |
| AUC0–6 μg · h/ml) | 128.43 | 80.89 | 0.63 (0.49, 0.80) | <0.001 | 0.65 (0.49, 0.86) | 0.003 |
a
The models are adjusted for age, sex, and weight. Visit 1 was during the intensive phase of TB treatment, while visit 2 took place during the continuation phase of TB treatment. GMR, geometric mean ratio.